All Your Cell Counting Questions, Answered

… And Four Important Variables to Consider

– 8 min read

Cell counting can provide great insight into the state of your cell culture. Here, we answer all your burning questions on this topic, so get ready for the ride!

Key points:

  • Quantifying cells helps you determine their viability and growth pattern
  • Manual methods revolve around the use of hemocytometers observed through light microscopy
  • Automated instruments are either based on electric impedance, flow cytometry or image cytometry
  • Time-consumption, accuracy and consistency vary between these approaches

What is Cell Counting?

A simple yet important question. Some may say that cell counting is just counting cells. But in reality, it’s so much more than that. Among many things, cell counting is…

  • routine. Maintain consistency in experiments that involve cells by checking in on them. Making sure that they look and act as expected keeps you one step ahead.
  • insightful. It can tell you about cell viability as well as the standard deviation and variance if you perform the cell count multiple times. Of course, other factors than just the condition of the cells impact these numbers—more on this later.
  • caring. Caring for your cells and their health. Keep an eye on how they are doing in their culture medium and give them the best possible conditions to thrive.
  • being prepared. Plan and maintain a cell culture until it’s needed. It’s crucial to do this in different assays or protein production, for example, to ensure the desired results.
scientist with pipette in laboritory


What Are The Methods?

The main distinction in the field of cell counting is made between manual and automated techniques. Both methods of counting cells require cell staining before being counted to differentiate between the dead and viable cells in a sample.

Especially in manual cell counting, trypan blue is often used to stain dead cells as it isn’t membrane permeable1. Other stains include propidium iodide (PI), erythrosine B, acridine orange (AO) and DAPI.

Let’s start by looking at manual method.


Manual Cell Counting

It’s a method that most of us are familiar with. You have a diluted cell culture (fx in PBS) which you stain. You can then count the cells using a hemocytometer and a tally counter2. For a more in-depth walkthrough, see our blog on hemocytometers.

Advantages: Most equipment only needs to be purchased once. The only interchangeable part is the hemocytometer, (which you can choose to wash and reuse), making it an extremely cheap way to count cells.

To fill one of the hemocytometer chambers you’ll only need 10 μl of diluted cell suspension, which allows you to do a count even if the volume of your cell culture is small.

Disadvantages: The method is prone to a lot of subjectivity regarding what defines a cell, and this can affect the accuracy of the total cell count. This problem is especially apparent when working with aggregated cells.

Also, you will need experience in handling a microscope to be able to count cells. It takes a relatively long time to count the cells manually and that also amounts to higher labor costs.

manually counting cells

Let’s not forget the automated methods

Automated cell counters are divided into three types. It might seem a bit intimidating, but fear not—we’ll walk you through them.


Electrical Impedance-Based

Cell counters that are based on electrical impedance are also known as Coulter counters. These are based on the Coulter principle which states that the impedance of a particle in an electric current is different from that of its buffer or medium. The cells are counted by pumping them through an aperture and measuring the resistance 3.

Advantages: Coulter counters can count a lot of different types of particles including both nucleated and non-nucleated cells. Also, you get a true number of cells in each volume as opposed to the manual method where the cells/μl are estimated based on the cell count of a small area.

Disadvantages: This method doesn’t allow you to differentiate between viable and non-viable cells as opposed to image-based methods. Other limitations include: Small particles can go unnoticed, aggregates are counted as one cell and your choice of cell medium is limited to electrolytes.


Optical/Flow Cytometry-Based

Cells can also be counted and characterized by flow cytometry. Here, an excitation laser is directed towards the bypassing cells and the light scatter is passed through a variety of filters and detectors. These signals are then amplified and passed on to a computer system for analysis3.

Advantages: It’s a time-saving method that allows for fast and precise cell counting compared to manual cell counting. You can determine cell viability using this method by staining the cells with both a membrane-permeable and a membrane-impermeable fluorescent dye. The excitation wavelength of the viable cells will differ from the viable ones and reflect the cell viability.

Disadvantages: The essential tool here is a flow cytometer which is an expensive instrument compared to image-based cell counters (see the section below). Adding onto this cost, you will need training in using a flow cytometer to count cells. Difficulties can occur when quantifying cells that tend to clump.


Image-Based Cytometry

Image-based cytometry is highly dependent upon the image processing of cells, using machine learning and advanced algorithms tailored to the specific cell counting protocol.

These images are either taken through a brightfield or fluorescence microscope objective3.

Advantages: The computer-based cell recognition of this method allows for the quantification of aggregates.

It also ensures consistency regarding the cell counting protocol because the microscopy is handled by a computer to eliminate human bias.

Disadvantages: An image cytometer is a costly instrument compared to a hemocytometer. Many of these cell counters also require special one-time-use slides or cassettes for loading the sample.



Four Important Variables to Consider

Before committing to either manual or automated cell counting, here are some factors that you should consider:

#1 Price Matters!

A common standpoint is that manual cell counting is significantly cheaper because of the low cost of the hemocytometer as opposed to the cost of automated instruments. However, you need to take into consideration that it has the additional cost of human labor (which amounts to a LOT in fact).

It’s also prone to many errors2 and as we all know, errors are expensive. These expenses are eliminated when using an automated counter.


#2 Consistency is Key

Every scientist knows that for their experimental results to be valid, a researcher from another lab should be able to follow the same protocol and get the same results.

This reproducibility is ensured with automated cell counters because of the high degree of standardization as opposed to manual cell counting where other factors interfere with the results – more on this in section #3.


#3 Is the Human Eye Accurate Enough?

You’ve surely tried to carry out duplicate cell counts only to find that the numbers vary significantly from each other even though you used the same sample!

This problem is especially seen when manually counting cells, partly because of the human bias (which decides what is defined as a cell) and partly because a hemocytometer gets easily overfilled. You can avoid these issues with automated cell counters since human errors would be eliminated. Learn more.


#4 Fast-Tracking the Process

Initially automated cell counting can be time-consuming because it requires training, but once you get the hang of it, you will be speedier than with the manual method.

Manual cell counting is time-consuming because the cells are counted one by one and calculations like the total cell count and cell viability are done manually afterwards. With an automated method, all this work is handed over to the cell counter, freeing up time for all the other exciting projects in your lab!

Thinking Scientist

Industries that Rely on Cell Counting

Now that you know (almost) everything about cell counting, we’d like to fill you in on what you can use it for.

  • Cell therapy: Cell counting is used to determine the right doses for cell-based therapeutics as well as a tool to ensure that the product is standardized4.
  • Bioprocessing: In this field, cell counting is used to routinely monitor the condition i.e. growth and viability of the cell cultures in the bioreactors. This allows for optimization of the output based on the cell culture’s growth phase5.
  • Drug development: After cells have been treated with potential drug candidates, cell counting is used to monitor viability. It’s also crucial to ensure reproducibility6.

So, as you can see, the limits are endless. Whether it’s done manually or automated, cell counting has a lot of applications that will surely complement your lab work and help you obtain better results.

On that note, what are you waiting for? Go and try some of these different methods and find out which one is best suited for your lab. Happy counting!


Further reading


References

  1. Johnson, S., Nguyen, V. and Coder, D. (2013), Assessment of Cell Viability. Current Protocols in Cytometry, 64: 9.2.1-9.2.26
  2. Electron Microscopy Sciences: Neubauer Haemocytometry
  3. Vembadi A, Menachery A, Qasaimeh MA. Cell Cytometry: Review and Perspective on Biotechnological Advances. Front Bioeng Biotechnol. 2019;7:147
  4. Sarkar S, Pierce L, Lin-Gibson S, Lund S (2019). Standards Landscape in Cell Counting: Implications for Cell & Gene Therapy. Cell and Gene Therapy Insights. 5. 117-131. 10.18609/cgti.2019.016.
  5. Butler M, Spearman M, Braasch K (2014). Monitoring Cell Growth, Viability, and Apoptosis. Methods in molecular biology (Clifton, N.J.). 1104. 169-92. 10.1007/978-1-62703-733-4_12.
  6. Niepel M, Hafner M, Mills CE et al. A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. Cell Syst. 2019 Jul 24;9(1):35-48.e5

By Christina Psaradaki, Student Assistant at ChemoMetec
Christina Psaradaki studies Human Life Science Engineering at the Technical University of Denmark. At ChemoMetec, she writes for the Cell Counting Blog.

Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://chemometec.com/cell-counting-questions-answered/

Weiterlesen

Ad hoc: Evotec SE – Bayer discontinues clinical development candidate eliapixant (BAY1817080); Evotec regains the rights to all P2X3 assets

Evotec SE announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-se—bayer-discontinues-clinical-development-candidate-eliapixant-bay1817080-evotec-regains-the-rights-to-all-p2x3-assets-6141

Weiterlesen

Evotec expands sustainability at Dorothy Crowfoot Hodgkin Campus

Evotec SE announced today that the Company plans to significantly invest in its site at Milton Park, named Dorothy Crowfoot Hodgkin Campus, to reduce the CO2 emissions. The project will help to achieve the company’s carbon neutral targets. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-sustainability-at-dorothy-crowfoot-hodgkin-campus-6140

Weiterlesen

Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

Evotec announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell (“iPSC”)-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-ipsc-based-drug-discovery-partnership-with-boehringer-ingelheim-in-ophthalmology-6136

Weiterlesen

Evotec and Lilly enter into drug discovery collaboration in metabolic diseases

Evotec SE announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-lilly-enter-into-drug-discovery-collaboration-in-metabolic-diseases-6132

Weiterlesen

Evotec partner Celmatix achieves milestone for PCOS drug programme

Evotec partner Celmatix, a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-celmatix-achieves-milestone-for-pcos-drug-programme-6134

Weiterlesen

Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach

Evotec SE announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer’s through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-neuroscience-collaboration-with-bristol-myers-squibb-to-include-new-targeted-protein-degradation-approach-6130

Weiterlesen

Symrise forciert internationale Expansion in Pet Nutrition durch Übernahme von Schaffelaarbos

— Akquisition ergänzt Aktivitäten von Symrise im Bereich Heimtiernahrung — Schaffelaarbos ist ein führender Hersteller nachhaltig gewonnener Proteine aus Eiern
— Symrise strebt führende Rolle bei Verwertung von Eiern an und trägt mit nachhaltigen Proteinen für Tierfutterindustrie zur positiven Kreislaufwirtschaft im Lebensmittelbereich bei
— Abschluss der Transaktion im Januar 2022 erwartet Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-forciert-internationale-expansion-in-pet-nutrition-durch-uebernahme-von-schaffelaarbos/

Weiterlesen

Symrise ergänzt seine Produktionsstätten für 1,2-Alkandiole um eine neue Anlage in Granada, Spanien

— Zusätzliche Produktionsanlage für kosmetische multifunktionale Inhaltsstoffe
— Erhöhte Produktionskapazität für qualitativ hochwertige Produkte
— Reaktion auf global wachsende Nachfrage Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-ergaenzt-seine-produktionsstaetten-fuer-12-alkandiole-um-eine-neue-anlage-in-granada-spanien/

Weiterlesen

Evotec receives € 7.5 m grant for development of COVID-19 therapeutic

Evotec SE announced today that the Company has been selected by the German Federal Ministry of Education and Research (“BMBF”) to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID 19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-eur-75-m-grant-for-development-of-covid-19-therapeutic-6128

Weiterlesen